Is atomoxetine effective in some comorbid mental disorders in ADHD?

Open access

Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) is connected with high level of psychiatric comorbidity in paediatric population. Depressive disorder is common comorbid disorder co-existing with ADHD. Atomoxetine is worldwide approved for treatment of ADHD in paediatric population; in addition atomoxetine is effective and safe in treatment of some comorbid disorders in ADHD. Pharmacotherapy of depression is limited and residual symptoms are common. Fluoxetine is currently considered to be the gold standard of treatment of depression, but effectiveness of acute phase of treatment is not sufficient. Atomoxetine as a selective noradrenaline reuptake inhibitor or olanzapine as a multi receptors antagonist drug in combination with fluoxetine could be perspective augmented treatment strategy of depression just for their antidepressant effect. The aim of our following study is to evaluate and compare effectiveness and safety of monotherapy and combined/augmented therapy in acute phase of depression treatment in adolescence, as well as introduce complex modern research methodology of effectiveness and safety of treatment.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] American Psychiatric Association (APA). Disorders usually first diagnosed in infancy childhood or adolescence. Diagnostic and statistical manual of mental disorders 4th edn text revision. Washington DC: American Psychiatric Association. 2000.

  • [2] Bangs ME Graham JE Thomas JS et al.: Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17(4):407-420.

  • [3] Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90(suppl. L):126-129.

  • [4] Biederman J Faraone S Milberger S et al. A prospective 4-year follow-up study of attention deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996;53:437-446.

  • [5] DeFillipis M Wagner KD. Management of Treatment-Resistant Depression in Children and Adolescents. Pediatr Drugs. 2014;16:353-361.

  • [6] Detke HC DelBello MP Landry J Usher RW. Olanzapine/ Fluoxetine combination in children and adolescents with bipolar I depression: a randomized double-blind placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2015;54(3):217-224.

  • [7] Emslie GJ Heiligenstein JH Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebocontrolled randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1205-1215.

  • [8] Emslie GJ Rush AJ Weinberg WA et al. A double-blind randomized placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54(11):1031-1037.

  • [9] Emslie GJ Kennard BD Mayes TL et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry. 2008;165(4):459-467.

  • [10] Heiligenstein JH1 Hoog SL Wagner KD et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. J Child Adolesc Psychopharmacol. 2006;16(1-2):207-217.

  • [11] Hong JH Novick D Treuer T et al. Patient characteristics associated with treatment initiation among paediatric patients with Attention-Deficit/Hyperactivity Disorder symptoms in a naturalistic setting in Central Europe and East Asia. BMC Psychiatry. 2014;14:304.

  • [12] Kennard BD Emslie GJ Mayes TL et al. Sequential treatment with fluoxetine and relapse prevention CBT to improve outcomes in pediatric depression. Am J Psychiatry. 2014;171(10).

  • [13] Kratochvil CJ Newcorn JH Arnold LE et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915-924.

  • [14] Ledbetter M. Atomoxetine: a novel treatment for child and adult ADHD. Neuropsychiatr Dis Treat. 2006; 2(4):455-466.

  • [15] March J Silva S Petrycki S et al. Fluoxetine cognitive-behavioral therapy and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807-820.

  • [16] Ondrejka I. Hyperkineticka porucha v detskom veku. Ceskoslovenska pediatria. 2007; 6:406-414.

  • [17] Snircova E Kulhan T Ondrejka I Nosalova G. Atomoxetine as treatment in comorbidity of ADHD. Pokroky vo farmakologii v Slovenskej republike. 2013;8:105-109.

  • [18] Weiping X Lixiao S Jinsong Z. Comorbid anxiety and depression in school-aged children with attention deficit hyperactivity disorder (ADHD) and self reported symptoms of ADHD anxiety and depression among parents of school-aged children with and without ADHD. Shanghai Arch Psychiatry. 2015; 25; 27(6):356-367.

  • [19] Zerbe RL Rowe H Enas CG et al. Clinical pharmacology of tomoxetine a potential antidepressant. J Pharmacol Exp Ther. 1985;232:139-143.

Search
Journal information
Impact Factor


CiteScore 2018: 0.39

SCImago Journal Rank (SJR) 2018: 0.128
Source Normalized Impact per Paper (SNIP) 2018: 0.337

Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 262 77 4
PDF Downloads 154 58 4